Introduction
Renal transplant is the most preferred form of renal replacement therapy for end stage renal disease (ESRD). Over the last few decades, the development of highly potent immunosuppressive agents has played a dramatic role in improving graft survival and patient survival rate. However, it is associated with several short and long term complications.
Compared to the general population, a 2-7 fold increased incidence of malignancy has been reported in RTRs in various studies across different geographical areas. 1 The incidence of bladder cancer after renal transplant ranges from 0.08 to 2.10%. 2 Post-transplant malignancy is the third most common cause of death in RTRs after cardiac causes and infections. 3 The average age of presentation of bladder cancer in RTRs is usually 5th-6th decade. We present an interesting case of transitional cell carcinoma of the urinary bladder with highly fulminant course in a RTR in the 4th decade.
Case report
A 27-year-old man underwent live related renal allograft transplant for end stage renal disease secondary to chronic glomerulonephritis in 2003 with an uneventful recovery. The patient received triple immunosuppression (cyclosporine, mycophenolate mofetil and prednisolone). He was on regular follow up with a nadir serum creatinine of 0.8 mg/dL for 11 years after transplant.
In September 2014, he developed intermittent episodes of gross, total and painless hematuria. Urine cytology was positive for malignant cells. Ultrasound abdomen revealed diffuse bladder wall thickening predominantly on the right side along with intravesical clots with mild hydronephrosis of graft kidney. Serum creatinine was 2.8 mg/dL. Clot evacuation was done. MRI was attempted but the patient had claustrophobia. After explaining the risk and benefits of iodinated contrast, contrast enhanced CT abdomen and pelvis was done which showed heterogeneously enhancing polypoidal intraluminal mass measuring 5.3 cm Â 4.8 cm Â 3.4 cm at right lateral wall of the urinary bladder involving neoureteric orifice of transplanted kidney leading to upstream mild hydroureteronephrosis ( Fig. 1a-d ). Perivesical fat stranding was present with no regional lymphadenopathy. Both native kidneys were small and atrophic.
He underwent transurethral resection of bladder tumor (TURBT) with percutaneous nephrostomy (PCN) in the trans- Malignancies in renal transplant recipients (RTRs) usually have an aggressive biological behavior. They are detected at an advanced stage and have a poor survival rate. Post-transplant urinary bladder malignancy is an uncommon occurrence and most of these patients are in their 5th or 6th decade. We report a rare occurrence of bladder cancer in RTR in the 4th decade more than 10 years after renal transplantation with rapid progression and death within 12 weeks of diagnosis.
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cell carcinoma (stage T2G3). He was explained regarding the treatment options from radical cystectomy to bladder sparing and chemoradiotherapy. The patient opted for chemoradiotherapy. Following 2 cycles of chemoradiotherapy, the patient developed pancytopenia (hemoglobin -6.7 g%, total leukocyte count -2300/mL and platelet count -45,000/mL). Bone marrow biopsy revealed a hypocellular bone marrow. Chemotherapy was stopped and the dose of immunosuppressive agents was reduced. The patient was started on prophylactic antibiotics, antivirals and antifungals. Hematinics and blood transfusion were given along with colony stimulating factors (G-CSF) but the patient did not respond. Serum creatinine increased to 1.6 mg/dL.
During the course of treatment, the patient developed breathlessness and chest X-ray was suggestive of multiple secondary deposits in bilateral lung fields. CECT abdomen showed widespread liver and peritoneal metastasis. MRI brain was done for seizures and loss of conciousness which also showed metastatic deposits in bilateral cerebral hemispheres. Despite all efforts, the patient succumbed to widespread metastatic disease within 3 months of diagnosis of bladder malignancy.
Discussion
The increased incidence of malignancy in post-renal transplant recipient is well accepted in literature. 4 The exact pathophysiology is still unknown although several theories have been proposed. Putative factors are high-risk HPV (especially HPV16), cellular damage by prolonged use of immunosuppressants, 5 genetic polymorphism, etc. Higher incidence of bladder cancer has been reported in Asian population as compared to Europeans probably due to consumption of higher arsenic in form of underground water and intake of aristolochic acid in Chinese herbs. Bladder cancer in RTRs usually express aggressive biological behavior and is found at a higher stage with poor survival rate. 6 This is mainly due to the state of immunosuppression. The average time of presentation is within 4 years of transplant. 6 Immunosuppressants lead to impaired DNA repair capability, accelerated angiogenesis and impaired IL-2 mediated T-cell proliferation. 7 Treatment modalities are less well defined in bladder cancer patients in RTRs and limited patients undergo major extirpative surgery. Extirpative as well as reconstructive surgeries are difficult in RTRs due to previous surgery in same field. For low grade bladder tumor, TURBT is sufficient with intravesical instillation of mitomycin C in high risk group like large tumor or multifocal disease. Intravesical BCG is a relative contraindication for these patients due to risk of systemic BCGosis. 8 There are no guidelines regarding modulation of immunosuppressants in perioperative period, the usually accepted fact is that for localized disease no dose reduction is required. For muscle invasive disease radical cystectomy with urinary diversion in the form of ileal conduit/end ureterostomy/nephrostomy is most commonly described in literature. Orthotopic neobladder has been described well. 9 In case of locally advanced or metastatic growth palliative radiotherapy and chemotherapy have been tried with limited success. 10 Similar to lower tract urothelium, upper tract urothelium in native urinary tract is also at high risk of malignancy, so prophylactic bilateral nephroureterectomy with radical cystectomy is recommended for RTRs with good performance status. 
Conclusion
Post-transplant urinary bladder cancer is a rare entity but one should be vigilant whenever there is a clinical suspicion due to increased incidence in RTRs. Follow up ultrasonography with thorough evaluation of urinary tract can help in early detection of bladder mass. Most of the affected individuals have an advanced stage at presentation with fulminant course of disease. There is a small therapeutic window of time in which these patients can be managed with aggressive multimodality approach for better survival.
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